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Abstract
Purpose To assess the effects of preoperative
patient characteristics on clinical outcomes of
corneal crosslinking (CXL) treatment in
patients with progressive keratoconus.
Methods This retrospective study comprised
96 eyes of 96 patients who had unilateral
CXL treatment for progressive keratoconus.
All patients underwent a complete
ophthalmological examination and corneal
topography at baseline and 1 year. Subgroup
analyses were performed according to the age
(o30 andZ30 years), gender, preoperative
corrected distance visual acuity (CDVA, o0.3
and Z0.3 logMAR (log of the minimum
angle of resolution)), preoperative maximum
keratometry (K, o54 and Z54D), baseline
topographic cone location (central,
paracentral, and peripheral), and preoperative
thinnest pachymetry (o450 and Z450 mm) to
determine the associations between
preoperative patient characteristics and
outcomes (changes in visual acuity and
maximum keratometry) of CXL treatment.
Results In the entire study population,
mean CDVA and maximum K significantly
improved after CXL treatment (Po0.001).
Patients with a preoperative CDVA of 20/40
Snellen equivalent or worse (Z0.3 logMAR)
experienced more visual improvement after
CXL treatment (Po0.001). However, an age
Z30 years and a baseline thinnest
pachymetry less than 450 mm were found
significantly associated with more flattening
in maximum keratometry (P¼ 0.024, P¼ 0.005
respectively). Gender, preoperative maximum
K, and baseline topographic cone location
did not show significant effect on
postoperative visual acuity and maximum
keratometry (P40.05).
Conclusions In patients with progressive
keratoconus, age, baseline visual acuity, and
baseline thinnest pachymetry seem to affect
the success of the CXL treatment.
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Introduction
Keratoconus is a non-inflammatory ectatic
corneal disorder.1 Major clinical findings are
progressive stromal thinning and visual
deterioration secondary to irregular
astigmatism, myopia, and central corneal
scarring.1,2 Conservative treatment modalities
such as spectacles and gas permeable rigid
contact lenses become insufficient for visual
rehabilitation in advanced stages of keratoconus
and 10–20% of the patients need corneal
transplantation.2
Wollensak et al3,4 introduced corneal collagen
crosslinking (CXL) using riboflavin and
ultraviolet A (UVA) as a new hope for treatment
of progressive keratoconus. Studies concluded
that CXL is an effective procedure to arrest
the progression of keratoconus by increasing
biomechanical stability of the cornea.4–6
Moreover, significant improvements in visual
acuity and keratometry (K) readings after CXL
treatment could be considered as a regression in
disease severity.7–10
Although the efficacy of CXL treatment has
been shown in many studies, there is little
evidence about the influence of preoperative
patient characteristics on clinical outcomes of
CXL treatment.8–10 In this study, we aimed to
assess the effects of initial demographic and
topographic properties on outcomes of CXL
treatment in patients with progressive
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This retrospective study comprised 96 eyes of 96 patients
who underwent unilateral CXL treatment for progressive
keratoconus. The study was performed in adherence to
the tenets of the Declaration of Helsinki and local ethics
committee approved the methodology. Inclusion
criteria were biomicroscopic examination and corneal
topography consistent with keratoconus, inferior–
superior ratio on topographic map 41.5, at least 18 years
of age, thinnest corneal pachymetry of Z400 mm.
Progression was defined as Z1 D steepening of
maximum keratometry or an increase of Z1.00 D in
manifest cylinder or an increase of Z0.50 D in manifest
refraction spherical equivalent in 2 years. Eyes with
prior corneal surgery or scarring were excluded from
the study.
Examinations
All patients underwent detailed ophthalmological
examinations that included corrected (including contact
lens) distance visual acuity (CDVA) measurement with
Snellen charts, slit-lamp biomicroscopic examination,
applanation tonometry, and dilated funduscopic
examination. Visual acuity in Snellen format was
converted to the logMAR (log of the minimum angle
of resolution) equivalent for statistical analysis.11 The
mean CDVA was noted at baseline and 1 year after
CXL treatment.
New generation anterior segment tomography devices
are capable of determining the topography and
pachymetry of the entire cornea.12–14 In this study,
corneal topography (Allegro Oculyzer, WaveLight AG,
Erlangen, Germany) was conducted with undilated
pupils under scotopic conditions by a single experienced
technician. Scans were taken in automatic mode with
proper quality. Maximum keratometry and corneal
pachymetry at the thinnest location were recorded at
baseline and 1 year after CXL treatment.13,14 Cone
location was determined according to the topographic
coordinates of maximum keratometry as follows: central
cone (maximum K within the central 3 mm optical zone),
paracentral cone (3–5 mm optical zone), and peripheral
cone (outside the central 5 mm optical zone).
Subgroups and cutoff values were created in
accordance with the current literature as follows: age
(o30 and Z30 years), gender, preoperative CDVA (o0.3
and Z0.3 logMAR), preoperative maximum K (o54 and
Z54 D), baseline topographic cone location (central,
paracentral, and peripheral cone), and preoperative
thinnest pachymetry (o450 and Z450 mm) to analyze the
relationship between preoperative patient characteristics
and improvements in CDVA and maximum K after CXL
treatment.
Surgical procedure
CXL was performed under sterile conditions using
topical anesthesia as described by Wollensak.4 Central
9.0 mm corneal epithelium was removed by mechanical
debridement. Isotonic riboflavin solution (0.1% in 20%
dextran T500 solution) was instilled every 2 min for
30 min until riboflavin absorption was observed in the
corneal stroma and anterior chamber under
biomicroscopic examination. Then, the cornea was
exposed to UVA irradiation at the wavelength of 365 nm
and surface irradiance of 3 mW/cm2. During the UVA
exposure, isotonic riboflavin solution instillation was
continued every 2 min for 30 min. Postoperatively, a soft
contact lens was placed until corneal epithelial healing
completed. Topical antibiotic and corticosteroid drops
were administered and continued four times daily for
1 week and 2 weeks, respectively.
Statistical analysis
Statistical analysis was performed with the Statistical
Package for Social Sciences software version 16.0
(SPSS Inc, Chicago, IL, USA). Results were expressed as
mean±SD. A paired t-test was used to analyze the
changes in mean CDVA and maximum K between
baseline and 1 year. Comparison of the quantitative data
(changes in mean CDVA and maximum K) between two
groups was performed by independent samples t-test.
However, non-parametric tests (Wilcoxon signed ranks
test and Mann–Whitney U-test) were used to analyze the
effects of preoperative topographic cone location on
mean CDVA and maximum K. A P-value less than 0.05
was considered statistically significant at 95% confidence
interval.
Results
Ninety-six eyes of ninety-six patients who had unilateral
CXL treatment for progressive keratoconus were
included in this retrospective study. The study group
consisted of 39 (40.6%) male and 57 (59.4%) female with a
mean age of 29.42±9.34 years (Table 1). All patients had
1-year follow-up. In the entire cohort, mean CDVA
significantly improved from 0.39±0.29 logMAR (20/49
Snellen) to 0.28±0.22 logMAR (20/38 Snellen; Table 2,
Po0.001) and the maximum K significantly decreased
from 54.54±5.50 D to 53.52±5.18 D between baseline and
1 year after CXL treatment (Table 2, Po0.001).
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The effects of preoperative patient characteristics on
changes in CDVA and maximum K after CXL treatment
were assessed.
Subgroup analyses according to the preoperative
patient data
Age Patients with o30 years of age (n¼ 54): The mean
CDVA significantly improved from baseline 0.34±0.23
logMAR (20/43 Snellen) to 0.21±0.15 logMAR
(20/32 Snellen) at 1-year after CXL treatment (Po0.001),
whereas improvement in maximum K (from
53.62±4.90 D to 53.06±5.03 D) was not statistically
significant (P¼ 0.61).
Patients withZ30 years of age (n¼ 42): The improvement
in mean CDVA was not statistically significant (from
0.44±0.35 logMAR, 20/55 Snellen, to 0.36±0.27
logMAR, 20/45 Snellen, P¼ 0.074) between baseline and
1 year, whereas maximum K significantly decreased after
CXL treatment (from 55.72±6.12 D to 54.12±5.37 D,
Po0.001).
Comparison of the postoperative changes in CDVA and
maximum K between groups: After CXL treatment,
the patients with Z30 years of age experienced more
flattening in maximum K compared with that of the
patients with o30 years of age (P¼ 0.024), whereas there
was no significant difference between two groups in
terms of change in CDVA (P¼ 0.442).
Gender Males (n¼ 39): The mean CDVA (from 0.35±0.25
logMAR, 20/44 Snellen, to 0.27±0.22 logMAR, 20/37
Snellen, P¼ 0.034) and maximum K (from 53.95±6.04 D
to 53.28±6.06 D, P¼ 0.005) significantly improved
between baseline and 1 year after CXL treatment.
Females (n¼ 57): There were significant improvements
in mean CDVA (from 0.41±0.32 logMAR, 20/51 Snellen,
to 0.28±0.22 logMAR, 20/38 Snellen, P¼ 0.001) and
maximum K (from 54.94±5.18 D to 53.69±4.53 D,
P¼ 0.001) after CXL treatment.
Comparison of the postoperative changes in CDVA and
maximum K between groups: There were no significant
differences regarding the changes in CDVA and
maximum K between males and females (P¼ 0.501,
P¼ 0.183, respectively).
Preoperative CDVA CDVA o0.3 logMAR (n¼ 39): The
mean CDVA did not show significant improvement
(from 0.16±0.06 logMAR, 20/28 Snellen, to 0.16±0.13
logMAR, 20/28 Snellen, P¼ 0.905), whereas the decrease
in maximum K was statistically significant (from
52.42±4.12 D to 51.66±3.92 D, P¼ 0.002).
CDVA Z0.3 logMAR (n¼ 57): The mean CDVA
(from 0.54±0.29 logMAR, 20/69 Snellen, to 0.36±0.23
logMAR, 20/45 Snellen, Po0.001) and maximum
K significantly improved after CXL treatment
(from 55.98±5.94 D to 54.80±5.57 D, P¼ 0.001).
Comparison of the postoperative changes in CDVA and
maximum K between groups: The patients with a worse
baseline visual acuity (CDVA Z0.3 logMAR) showed
significant improvement in CDVA 1 year after CXL
treatment compared with that of the patients with a better
baseline visual acuity (CDVAo0.3 logMAR; Po0.001).
However, comparing two groups, the change in maximum
K was not statistically significant at 1 year (P¼ 0.316).
Preoperative maximum keratometry Maximum K o54D
(n¼ 52): The baseline CDVA (from 0.28±0.17 logMAR,
20/38 Snellen, to 0.21±0.17 logMAR, 20/32 Snellen,
P¼ 0.009) and maximum K significantly improved
(from 50.54±2.10 D to 49.74±2.31 D, P¼ 0.003) after CXL
treatment.
Maximum K Z54D (n¼ 44): After CXL treatment,
mean CDVA (from 0.51±0.35 logMAR, 20/64 Snellen,
to 0.35±0.25 logMAR, 20/44 Snellen, P¼ 0.002) and
maximum K significantly improved (from 59.26±4.51 D
to 58.00±3.89 D, P¼ 0.003).
Table 1 Demographic data of the study group (n¼ 96)
Characteristic Value
Gender
Male, n (%) 39 (40.6)
Female, n (%) 57 (59.4)
Age, years (mean±SD) 29.42±9.34
18–29, n (%) 54 (56.2)
30–50, n (%) 42 (43.8)
Table 2 Changes in visual acuity and topographic data between baseline and 1 year after CXL treatment in the entire cohort (n¼ 96)
Baseline 1 Year P-value
CDVA (logMAR, mean±SD) (Snellen equivalent) 0.39±0.29 (20/49) 0.28±0.22 (20/38) o0.001
Maximum keratometry (diopters, mean±SD) 54.54±5.50 53.52±5.18 o0.001
Thinnest pachymetry (mm, mean±SD) 460.11±47.15 430.65±61.90 o0.001
Abbreviations: CDVA, corrected distance visual acuity; CXL, corneal collagen crosslinking. Bold values indicate statistical significance¼Po0.05, paired t-test.
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Comparison of the postoperative changes in CDVA and
maximum K between groups: There were no significant
differences between two groups in terms of change in
CDVA and maximum K after CXL treatment (P¼ 0.099,
P¼ 0.332, respectively).
Preoperative cone location. The study group comprised
only eyes with central and paracentral cones.
Central cone (n¼ 72): There were significant
improvements in mean CDVA (from 0.43±0.32
logMAR, 20/53 Snellen, to 0.30±0.23 logMAR, 20/39
Snellen, Po0.001) and maximum K (from 55.75±5.68 D
to 54.54±5.36 D, Po0.001) 1 year after CXL treatment.
Paracentral cone (n¼ 24): There were no significant
improvements in mean CDVA (from 0.24±0.09
logMAR, 20/34 Snellen, to 0.21±0.18 logMAR, 20/32
Snellen, P¼ 0.239) and maximum K (from 50.90±2.92 D
to 50.47±3.05 D, P¼ 0.057) at 1-year follow-up.
Comparison of the postoperative changes in CDVA and
maximum K between the groups: The changes in mean
CDVA and maximum K after CXL treatment did not
show significant differences between two groups
(P¼ 0.176, P¼ 0.160, respectively).
Preoperative thinnest pachymetry Thinnest pachymetry
o450 mm (n¼ 45): The baseline mean CDVA (from
0.44±0.35 logMAR, 20/55 Snellen, to 0.32±0.23
logMAR, 20/41 Snellen, P¼ 0.012) and maximum K
(from 57.79±5.52 D to 56.10±5.17 D, Po0.001)
significantly improved after CXL treatment.
Thinnest pachymetry Z450mm (n¼ 51): The mean CDVA
(from 0.34±0.23 logMAR, 20/43 Snellen, to 0.24±0.21
logMAR, 20/34 Snellen, P¼ 0.001) significantly
improved, whereas maximum K (from 51.67±3.67 D to
51.25±4.02 D, P¼ 0.124) did not show significant
improvement after CXL treatment.
Comparison of the postoperative changes in CDVA and
maximum K between groups: The maximum K
significantly decreased in thinner corneas (pachymetry
o450 mm) compared with that of the relatively thicker
corneas (pachymetry Z450mm; P¼ 0.005), whereas
there was no significant difference between the groups
with respect to improvement in CDVA (P¼ 0.627).
Postoperative changes in mean CDVA and maximum
K according to the preoperative factors are demonstrated
in Figures 1 and 2.
Discussion
CXL using photosensitizer riboflavin and UVA-light
has been introduced as a promising new treatment for
progressive keratoconus to reduce the need for corneal
transplantation.4 The treatment, as a photo-oxidative
procedure, enhances biomechanical stability of the
cornea because of synthesis of well-structured collagen
and new lamellar interconnections in the cornea.5,6,15
Numerous clinical studies agreed that CXL treatment
provides significant improvements in visual acuity and
maximum keratometry as well as halting the progression
of keratoconus.7,8,16,17 However, it is still unclear whether
baseline demographic and topographic characteristics
influence postoperative outcomes. Therefore, we sought









































































































Figure 1 Change in mean corrected distance visual acuity (CDVA) between baseline and 1 year after CXL treatment in subgroups
(*indicates statistically significant difference between two groups, Po0.05).
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maximum K, topographic cone location, and preoperative
thinnest corneal pachymetry on improvements in CDVA
and maximum K at 1 year after CXL treatment. In the
entire study group, the improvements in CDVA and
maximum keratometry after CXL treatment were in
agreement with the previous studies.9,10,18–20
In the current literature, a small number of studies
investigated the effects of preoperative patient
characteristics on outcomes of CXL treatment. Koller
et al21 evaluated the effects of maximum K, preoperative
CDVA, and age on complication and failure rates of CXL
treatment for primary keratectasia. They suggested that
age older than 35 years and a preoperative CDVA better
than 20/25 (Snellen equivalent) were significant risk
factors for complications (percentage of eyes losing two
or more Snellen lines) and a preoperative maximum K
458 D was identified a significant risk factor for failure
(percentage of eyes with continued progression). On the
contrary, another study by Koller et al22 demonstrated
that a preoperative maximum K of 454.00 D was a
significant positive preoperative predictor of corneal
flattening 1 year after CXL treatment. Similarly, a
multifactorial analysis by Greenstein and colleagues
revealed that patients with initial worse CDVA (r20/40
Snellen equivalent) and a higher keratometry (Z55 D)
were most likely to benefit from CXL treatment.23
In our study, a preoperative CDVA r20/40 Snellen
equivalent was found significantly related with
postoperative visual improvement. Furthermore,
patients with an age Z30 years and a thinnest corneal
pachymetry less than 450 mm significantly experienced
more flattening in maximum K. However, gender,
preoperative maximum K, and preoperative topographic
cone location did not affect postoperative changes in
mean CDVA and maximum K. Another study by
Greenstein et al24 demonstrated more topographic
flattening in eyes with centrally located cones compared
with that of the peripherally located cones 1 year after
CXL treatment, whereas differences among cone groups
were not found statistically significant with respect to
change in visual acuity.
It has been concluded that CXL is a safe and effective
procedure for the treatment of progressive keratoconus,
whereas it is still unclear which patients are more likely to
benefit from the treatment. In clinical practice, it can be
valuable to predict success of the treatment to give patients
satisfactory information about postoperative course.
In conclusion, our study evaluated baseline
demographic and topographic data to determine
preoperative predictors of CXL treatment efficacy. Age,
preoperative CDVA, and thinnest corneal pachymetry
appear to influence the efficacy of CXL treatment.
Summary
What was known before
K Previous studies demonstrated the efficacy of corneal
collagen crosslinking (CXL) treatment in patients with
keratoconus.
K Preoperative predictors of CXL efficacy were not
completely elucidated.
What this study adds
K Patients with an older age (Z 30 years), a worse baseline
corrected visual acuity (r20/40 Snellen equivalent), and
a thinner baseline pachymetry (o450mm) most likely to
benefit from CXL treatment.
K Preoperative corrected visual acuity was significantly
related with visual improvement, whereas age
and baseline thinnest corneal pachymetry showed


















































































































Figure 2 Mean decrease in maximum keratometry between baseline and 1 year in subgroups (*indicates statistically significant
difference between two groups, Po0.05).
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